posted on 2017-07-13, 00:00authored byShengmin Zhou, Yueqiang Wang, Jörg J. Jacoby, Yuanrong Jiang, Yaqiong Zhang, Liangli Lucy Yu
Obesity is related to an increasing
risk of chronic diseases. Medium-
and long-chain triacylglycerols (MLCT) have been recognized as a promising
choice to reduce body weight. In this study, three MLCT with different
contents of medium-chain fatty acids (MCFA) (10–30%, w/w) were
prepared, and their effects on lipid metabolism and fecal gut microbiota
composition of C57BL/6J mice were systematically investigated. MLCT
with 30% (w/w) MCFA showed the best performance in decreasing body
weight gain as well as optimizing serum lipid parameters and liver
triacylglycerol content. The expression levels of genes encoding enzymes
for fatty acid degradation increased markedly and expression levels
of genes encoding enzymes for de novo fatty acid
biosynthesis decreased significantly in the liver of mice treated
with MLCT containing 30% (w/w) MCFA. Interestingly, the dietary intake
of a high fat diet containing MLCT did significantly decrease the
ratio of Firmicutes to Bacteroidetes and down-regulate the relative abundance of Proteobacteria that may attribute to weight loss. Furthermore, we found a notable
increase in the total short-chain fatty acid (SCFA) content in feces
of mice on a MLCT containing diet. All these results may be concomitantly
responsible for the antiobesity effect of MLCT with relatively high
contents of MCFA.